Seeking to bolster the safety of pharmaceuticals sold in Thailand, the country’s Food and Drug Administration (FDA) is imposing minimum standards established by the World Health Organization to ensure the quality and integrity of medicines throughout the supply chain.
Under the Good Distribution Practice (GDP) standards that will be required for pharmaceuticals beginning in January 2022, regulators will audit suppliers, manufacturers, importers, distributors, third party logistic companies, transporters, pharmacies, hospitals, and others to ensure they adhere to the WHO-approved quality assurance standards.
The new standards may increase operational costs for pharmaceutical companies operating in Thailand but are an integral part of ramping up quality assurance in the country as its market for such products rapidly grows.